Ocrelizumab Benefit Confirmed in Older Patients With MS : vi

The relapse benefit of ocrelizumab in multiple sclerosis is confirmed for the first time in patients 60 and older starting therapy, say researchers in findings they hope will inform choices.

Related Keywords

Monash , South Australia , Australia , Melbourne , Victoria , Milan , Lombardia , Italy , Australian , Yi Chao Foong , Ocrelizumab Ocrevus , Pavan Bhargava , Americas Committee For Treatment , Johns Hopkins Precision Medicine Center , Research In Multiple Sclerosis , Central Clinical School , European Committee For Treatment , Monash University , Department Of Neuroscience , Joint European Committee , Multiple Sclerosis Americas Committee , Multiple Sclerosis , Expanded Disability Status Scale , Medscape Medical , Multiple Sclerosis Ms , Us , Disability , Europe , European , Geriatrics Elder Care , Disease Modifying Therapy , Mt , Facial , Monoclonal Antibody , Etuximab , Ituximab , Multiple Sclerosis Treatment , Als Treatment , Reatment Of Multiple Sclerosis , Reatment Of Ms , Precision Medicine , Biologic Therapy , Genomics , Genomic Medicine , Edicine Genomic ,